These results may represent a new molecular mechanism for hepatic steatosis and provide additional evidence for the therapeutic treatment of NAFLD using inhibitors of mTOR in patients with metabolic syndrome. The gene discussed is MTOR; the disease is metabolic dysfunction-associated steatotic liver disease.